NEU.ASX: Response to ASX Aware Letter

Response to ASX Aware Letter

Stock	Neuren Pharmaceuticals Ltd (NEU.ASX)
Release Time	19 Jan 2026, 9:10 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Neuren Pharmaceuticals Responds to ASX Aware Letter

Key Points

Neuren considers the DAYBUE global net sales projection to be material information
Neuren became aware of the information on January 14, 2026 and promptly disclosed it
Neuren has reasonable grounds for the DAYBUE sales projection based on Acadia's disclosures

Full Summary

Neuren Pharmaceuticals has provided a detailed response to an ASX aware letter regarding its recent announcement about Acadia Pharmaceuticals' projection of DAYBUE global net sales reaching ~US$700m in 2028. Neuren confirms it considers this information to be material, as royalties and milestone payments from DAYBUE are currently Neuren's sole source of product revenue. Neuren became aware of the information on January 14, 2026 from Acadia's announcement and conference presentation, and promptly disclosed it to the market. Neuren explains that it reviewed the information, including Acadia's stated assumptions, and believes it has reasonable grounds for the disclosure in line with ASIC's Regulatory Guide 170. Neuren states it is in compliance with the ASX Listing Rules, particularly Rule 3.1 on continuous disclosure. The responses have been authorized and approved by Neuren's Board.

Guidance

Acadia Pharmaceuticals projected DAYBUE global net sales to reach ~US$700m in 2028.